INSYS Therapeutics, Inc. (NASDAQ:INSY) Q4 2018 Earnings Conference Call - Final Transcript
Mar 07, 2019 • 05:00 pm ET
Good day, ladies and gentlemen, and welcome to the INSYS Therapeutics Fourth Quarter 2018 Earnings Conference Call. (Operator Instructions)
It is now my pleasure to turn the conference over to your host, Ms. Jackie Marcus, Alpha IR. Please go ahead.
Thank you, Haley. Welcome to the INSYS Therapeutics Fourth Quarter 2018 Results Conference Call. With me on today's call are President and Chief Executive Officer, Saeed Motahari; Chief Financial Officer, Andy Long; General Counsel and Chief Legal Officer, Mark Nance; along with Dr. Venkat Goskonda, Senior Vice President of Research and Development; and Dr. Ahmed Elkashef, Vice President of Clinical Development.
Earlier today, the company issued a press release detailing financial results for the fourth quarter ended December 31, 2018. You can access these materials through the Investors section at the company's website or you can also access a webcast replay of this call later today.
Before we continue, I would like to remind everyone that all statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company's future performance are considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to company management as of today and involve risks and uncertainties, including those noted in today's press release and the company's filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements.
INSYS Therapeutics specifically disclaims any intent or obligation to update these forward-looking statements except as required by law.
In addition to reporting all financial information required in accordance with the generally accepted accounting principles, the company is also reporting adjusted EBITDA, adjusted net loss and adjusted net loss per diluted share, which are non-GAAP financial measures. Since adjusted EBITDA, adjusted net loss and adjusted net loss per diluted share are non-GAAP financial measures, they should not be used in isolation or as a substitute for consolidated statements of comprehensive income or loss and cash flow data prepared in accordance with GAAP. In addition, the company's definitions of adjusted EBITDA, adjusted net loss, and adjusted net loss per diluted share may not be comparable to similarly titled non-GAAP financial measures reported by other companies. For a full reconciliation of adjusted EBITDA and adjusted net loss to GAAP net income, please see the attachments to the earnings release.
And with that, I'll turn the call over to the Company's President and Chief Executive Officer, Saeed Motahari.
Thank you, Jackie, and thanks to everyone on the line for joining us today. I would like to begin by covering our progress and our strategic priorities that are in line with our vision to become the leading cannabinoids and spray technology company, and then Andy will provide an overview of our financial results for the fourth quarter. I will conclude my remarks with discussion of our pipeline and after that, the team and I will take your questions.